Programa de formación docente en metacognición para la intervención en situaciones-problema de carácter interpersonal entre estudiantes

El estudio de la metacognición en procesos de intervención docente en situaciones-problema de carácter interpersonal entre estudiantes es un ámbito que, de acuerdo a la revisión de la literatura, ha sido poco explorado, por lo que la presente investigación apunta a dar respuesta a la pregunta ¿Cómo fortalecer las estrategias metacognitivas de planeación, control y evaluación en la intervención docente en situaciones- problema de carácter interpersonal entre estudiantes?Metacognition studies about teacher' s intervention in interpersonal character situations-problem among students is a field that, according to the reviewed literature, has not been deeply explored. The current investigation aims to answer the question How to strengthen the metacognitive strategies of planning, control and evaluation in teachers intervention in interpersonal character situations-problem among students?Magíster en EducaciónMaestrí

Programa de formación docente en metacognición para la intervención en situaciones-problema de carácter interpersonal entre estudiantes

El estudio de la metacognición en procesos de intervención docente en situaciones-problema de carácter interpersonal entre estudiantes es un ámbito que, de acuerdo a la revisión de la literatura, ha sido poco explorado, por lo que la presente investigación apunta a dar respuesta a la pregunta ¿Cómo fortalecer las estrategias metacognitivas de planeación, control y evaluación en la intervención docente en situaciones- problema de carácter interpersonal entre estudiantes?Metacognition studies about teacher' s intervention in interpersonal character situations-problem among students is a field that, according to the reviewed literature, has not been deeply explored. The current investigation aims to answer the question How to strengthen the metacognitive strategies of planning, control and evaluation in teachers intervention in interpersonal character situations-problem among students?Magíster en EducaciónMaestrí

Diseñar un modelo estratégico integral para el proceso de salud ocupacional con énfasis en gestión del conocimiento

Con el presente trabajo se pretende analizar de forma detallada la problemática identificada en la empresa en cuanto al Programa de Salud Ocupacional más específicamente en el Subprograma de Medicina Preventiva el cual no se está implementando en su totalidad y a causa de esto se está incrementando el índice de enfermedades laborales. Por tal motivo se hace necesario generar una propuesta que ayude a dar solución al problema con el fin de preservar la salud de los trabajadores y al mismo tiempo mejorar los procesos de la compañía y prever daños económicos.With the present work we intend to analyze in detail the problems identified in the company regarding the Occupational Health Program more specifically in the Subprogram of Preventive Medicine which is not being implemented in its entirety and because of this the index of occupational diseases. For this reason it is necessary to generate a proposal that helps to solve the problem in order to preserve the health of workers and at the same time improve the processes of the company and provide for economic damage

Deslizamientos submarinos y tsunamis en el Mar de Alborán. Un ejemplo de modelización numérica

Texto científico de carácter divulgativo.Texto científico de carácter divulgativo en el que se presenta un trabajo de modelado matemático y simulación numérica de un hipotético tsunami producido en el Mar de Alborán por un deslizamiento masivo de materiales en el flanco sur de la Dorsal de Alborán.Instituto Español de Oceanografía. Universidad de Málaga

Oseltamivir-Resistant Pandemic (H1N1) 2009 Virus, Mexico

During May 2009–April 2010, we analyzed 692 samples of pandemic (H1N1) 2009 virus from patients in Mexico. We detected the H275Y substitution of the neuraminidase gene in a specimen from an infant with pandemic (H1N1) 2009 who was treated with oseltamivir. This virus was susceptible to zanamivir and resistant to adamantanes and oseltamivir

La gestión ambiental del Instituto de Salud Carlos III: Evaluación del plan 2017-2020 y planificación ambiental del periodo 2021-2024

La presente publicación, que forma parte de los trabajos desarrollados por el grupo de seguimiento del Plan de Gestión Ambiental, tiene un doble objetivo; por una parte, describir y evaluar el Plan de Gestión Ambiental definido en 2016 para el periodo 2017-2020, y por otra, establecer las bases para la elaboración del nuevo PGA para el periodo 2021-2024. La cuestión medioambiental es un asunto que atañe directamente a la salud de la población. El Instituto de Salud Carlos III en materia medioambiental quiere contribuir dando ejemplo en la transformación del modelo existente, por ello ha integrado todas sus acciones en el marco de la planificación ambiental.Introducción y objetivos. El plan de gestión ambiental como instrumento de planificación y gestión en el sector público. Los recursos del ISCIII en los campus de Chamartín y Majadahonda. El plan de gestión ambiental 2017-2020. Estructura y líneas estratégicas. La gestión del agua y de los efluentes líquidos. La gestión de la energía y de las emisiones atmosféricas. La gestión del ruido. La gestión del suelo y de su contaminación. La gestión de los residuos. La gestión del arbolado y del patrimonio verde. La movilidad y el transporte sostenible. La gestión ambiental en la adquisición de bienes y servicios. La gestión de la salud ambiental. Seguimiento, difusión y formación del Plan de gestión ambiental. Una evaluación del PGA 2017-2020. Efectos de la pandemia de la Covid 19. Bases para la elaboración de un nuevo Plan de gestión ambiental. Acciones programadas, para el periodo 2021-2024.N

BNIP3 Is Involved in Muscle Fiber Atrophy in Late-Onset Pompe Disease Patients

Late-onset Pompe disease (LOPD) is a rare genetic disorder produced by mutations in the GAA gene and is characterized by progressive muscle weakness. LOPD muscle biopsies show accumulation of glycogen along with the autophagic vacuoles associated with atrophic muscle fibers. The expression of molecules related to muscle fiber atrophy in muscle biopsies of LOPD patients was studied using immunofluorescence and real-time PCR. BCL2 and adenovirus E1B 19-kDa interacting protein 3 (BNIP3), a well-known atrogene, was identified as a potential mediator of muscle fiber atrophy in LOPD muscle biopsies. Vacuolated fibers in LOPD patient muscle biopsies were smaller than nonvacuolated fibers and expressed BNIP3. The current data suggested that BNIP3 expression is regulated by inhibition of the AKT-mammalian target of rapamycin pathway, leading to phosphorylation of Unc-51 like autophagy activating kinase 1 (ULK1) at Ser317 by AMP-activated protein kinase. Myoblasts and myotubes obtained from LOPD patients and age-matched controls were studied to confirm these results using different molecular techniques. Myotubes derived from LOPD patients were likewise smaller and expressed BNIP3. Conclusively, transfection of BNIP3 into control myotubes led to myotube atrophy. These findings suggest a cascade that starts with the inhibition of the AKT-mammalian target of rapamycin pathway and activation of BNIP3 expression, leading to progressive muscle fiber atrophy. These results open the door to potential new treatments targeting BNIP3 to reduce its deleterious effects on muscle fiber atrophy in Pompe disease.Peer reviewe

Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients

Background Anti-CGRP monoclonal antibodies have shown notable effectiveness and tolerability in migraine patients; however, data on their use in elderly patients is still lacking, as clinical trials have implicit age restrictions and real-world evidence is scarce. In this study, we aimed to describe the safety and effectiveness of erenumab, galcanezumab and fremanezumab in migraine patients over 65 years old in real-life. Methods In this observational real-life study, a retrospective analysis of prospectively collected data from 18 different headache units in Spain was performed. Migraine patients who started treatment with any anti-CGRP monoclonal antibody after the age of 65 years were included. Primary endpoints were reduction in monthly migraine days after 6 months of treatment and the presence of adverse effects. Secondary endpoints were reductions in headache and medication intake frequencies by months 3 and 6, response rates, changes in patient-reported outcomes and reasons for discontinuation. As a subanalysis, reduction in monthly migraine days and proportion of adverse effects were also compared among the three monoclonal antibodies. Results A total of 162 patients were included, median age 68 years (range 65-87), 74.1% women. 42% had dyslipidaemia, 40.3% hypertension, 8% diabetes, and 6.2% previous cardiovascular ischaemic disease. The reduction in monthly migraine days at month 6 was 10.17.3 days. A total of 25.3% of patients presented adverse effects, all of them mild, with only two cases of blood pressure increase. Headache and medication intake frequencies were significantly reduced, and patient-reported outcomes were improved. The proportions of responders were 68%, 57%, 33% and 9% for reductions in monthly migraine days >= 30%,>= 50%,>= 75% and 100%, respectively. A total of 72.8% of patients continued with the treatment after 6 months. The reduction in migraine days was similar for the different anti-CGRP treatments, but fewer adverse effects were detected with fremanezumab (7.7%). Conclusions Anti-CGRP mAbs are safe and effective treatments in migraine patients over 65 years old in real-life clinical practice

The Fourteenth Data Release of the Sloan Digital Sky Survey: First Spectroscopic Data from the extended Baryon Oscillation Spectroscopic Survey and from the second phase of the Apache Point Observatory Galactic Evolution Experiment

The fourth generation of the Sloan Digital Sky Survey (SDSS-IV) has been in operation since July 2014. This paper describes the second data release from this phase, and the fourteenth from SDSS overall (making this, Data Release Fourteen or DR14). This release makes public data taken by SDSS-IV in its first two years of operation (July 2014-2016). Like all previous SDSS releases, DR14 is cumulative, including the most recent reductions and calibrations of all data taken by SDSS since the first phase began operations in 2000. New in DR14 is the first public release of data from the extended Baryon Oscillation Spectroscopic Survey (eBOSS); the first data from the second phase of the Apache Point Observatory (APO) Galactic Evolution Experiment (APOGEE-2), including stellar parameter estimates from an innovative data driven machine learning algorithm known as "The Cannon"; and almost twice as many data cubes from the Mapping Nearby Galaxies at APO (MaNGA) survey as were in the previous release (N = 2812 in total). This paper describes the location and format of the publicly available data from SDSS-IV surveys. We provide references to the important technical papers describing how these data have been taken (both targeting and observation details) and processed for scientific use. The SDSS website (www.sdss.org) has been updated for this release, and provides links to data downloads, as well as tutorials and examples of data use. SDSS-IV is planning to continue to collect astronomical data until 2020, and will be followed by SDSS-V.Comment: SDSS-IV collaboration alphabetical author data release paper. DR14 happened on 31st July 2017. 19 pages, 5 figures. Accepted by ApJS on 28th Nov 2017 (this is the "post-print" and "post-proofs" version; minor corrections only from v1, and most of errors found in proofs corrected

Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer

<p>Abstract</p> <p>Background</p> <p>The biological relevance of nuclear ErbB-2/HER2 (NuclErbB-2) presence in breast tumors remains unexplored. In this study we assessed the clinical significance of ErbB-2 nuclear localization in primary invasive breast cancer. The reporting recommendations for tumor marker prognostic studies (REMARK) guidelines were used as reference.</p> <p>Methods</p> <p>Tissue microarrays from a cohort of 273 primary invasive breast carcinomas from women living in Chile, a Latin American country, were examined for membrane (MembErbB-2) and NuclErbB-2 expression by an immunofluorescence (IF) protocol we developed. ErbB-2 expression was also evaluated by immunohistochemistry (IHC) with a series of antibodies. Correlation between NuclErbB-2 and MembErbB-2, and between NuclErbB-2 and clinicopathological characteristics of tumors was studied. The prognostic value of NuclErbB-2 in overall survival (OS) was evaluated using Kaplan-Meier method, and Cox model was used to explore NuclErbB-2 as independent prognostic factor for OS.</p> <p>Results</p> <p>The IF protocol we developed showed significantly higher sensitivity for detection of NuclErbB-2 than IHC procedures, while its specificity and sensitivity to detect MembErbB-2 were comparable to those of IHC procedures. We found 33.6% NuclErbB-2 positivity, 14.2% MembErbB-2 overexpression by IF, and 13.0% MembErbB-2 prevalence by IHC in our cohort. We identified NuclErbB-2 positivity as a significant independent predictor of worse OS in patients with MembErbB-2 overexpression. NuclErbB-2 was also a biomarker of lower OS in tumors that overexpress MembErbB-2 and lack steroid hormone receptors.</p> <p>Conclusions</p> <p>We revealed a novel role for NuclErbB-2 as an independent prognostic factor of poor clinical outcome in MembErbB-2-positive breast tumors. Our work indicates that patients presenting NuclErbB-2 may need new therapeutic strategies involving specific blockage of ErbB-2 nuclear migration.</p